Cargando…
A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form
AIMS AND OBJECTIVE: The aim of this study was to develop and validate a novel ultra-performance liquid chromatographic method for estimation of darunavir in a bulk and tablet dosage form. MATERIALS AND METHODS: The chromatographic separation was achieved using DIKMA Endoversil (2.1mm x 50mm, 1.7 µm)...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142922/ https://www.ncbi.nlm.nih.gov/pubmed/34084050 http://dx.doi.org/10.4103/jpbs.JPBS_337_19 |
_version_ | 1783696648498577408 |
---|---|
author | Biswal, Sabyasachi Mondal, Sumanta Mondal, Prasenjit |
author_facet | Biswal, Sabyasachi Mondal, Sumanta Mondal, Prasenjit |
author_sort | Biswal, Sabyasachi |
collection | PubMed |
description | AIMS AND OBJECTIVE: The aim of this study was to develop and validate a novel ultra-performance liquid chromatographic method for estimation of darunavir in a bulk and tablet dosage form. MATERIALS AND METHODS: The chromatographic separation was achieved using DIKMA Endoversil (2.1mm x 50mm, 1.7 µm) column. A mixture of 40% buffer (0.1% octa sulfonic acid) and 60% acetonitrile was used as a mobile phase with the isocratic elution mode and eluent was monitored at 281nm using UV detector. The method was continued and validated in accordance with International Conference on Harmonization Guidelines. Validation study revealed the specificity and reliability of the method. RESULTS: In this method, darunavir was eluted with retention time of 0.516 min. Calibration curve plots were found linear over the concentration ranges 10–50 μg/mL for darunavir. Limit of detection was 0.02 μg/mL and limit of quantification was found 0.07 μg/mL. The present method was also found stable in force degradation study. CONCLUSION: The empirical evidences of all the study results revealed the suitability of the estimation of darunavir in bulk and tablet dosage form without any interference from the excipients. |
format | Online Article Text |
id | pubmed-8142922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-81429222021-06-02 A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form Biswal, Sabyasachi Mondal, Sumanta Mondal, Prasenjit J Pharm Bioallied Sci Original Article AIMS AND OBJECTIVE: The aim of this study was to develop and validate a novel ultra-performance liquid chromatographic method for estimation of darunavir in a bulk and tablet dosage form. MATERIALS AND METHODS: The chromatographic separation was achieved using DIKMA Endoversil (2.1mm x 50mm, 1.7 µm) column. A mixture of 40% buffer (0.1% octa sulfonic acid) and 60% acetonitrile was used as a mobile phase with the isocratic elution mode and eluent was monitored at 281nm using UV detector. The method was continued and validated in accordance with International Conference on Harmonization Guidelines. Validation study revealed the specificity and reliability of the method. RESULTS: In this method, darunavir was eluted with retention time of 0.516 min. Calibration curve plots were found linear over the concentration ranges 10–50 μg/mL for darunavir. Limit of detection was 0.02 μg/mL and limit of quantification was found 0.07 μg/mL. The present method was also found stable in force degradation study. CONCLUSION: The empirical evidences of all the study results revealed the suitability of the estimation of darunavir in bulk and tablet dosage form without any interference from the excipients. Wolters Kluwer - Medknow 2021 2020-12-21 /pmc/articles/PMC8142922/ /pubmed/34084050 http://dx.doi.org/10.4103/jpbs.JPBS_337_19 Text en Copyright: © 2020 Journal of Pharmacy and Bioallied Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Biswal, Sabyasachi Mondal, Sumanta Mondal, Prasenjit A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form |
title | A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form |
title_full | A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form |
title_fullStr | A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form |
title_full_unstemmed | A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form |
title_short | A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form |
title_sort | novel ultra performance liquid chromatography-pda method development and validation for darunavir in bulk and its application to marketed dosage form |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142922/ https://www.ncbi.nlm.nih.gov/pubmed/34084050 http://dx.doi.org/10.4103/jpbs.JPBS_337_19 |
work_keys_str_mv | AT biswalsabyasachi anovelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform AT mondalsumanta anovelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform AT mondalprasenjit anovelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform AT biswalsabyasachi novelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform AT mondalsumanta novelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform AT mondalprasenjit novelultraperformanceliquidchromatographypdamethoddevelopmentandvalidationfordarunavirinbulkanditsapplicationtomarketeddosageform |